Skip to main content
. 2021 Aug 12;37(8):1461–1471. doi: 10.1093/ndt/gfab237

FIGURE 1.

FIGURE 1

SAPPHIRE study design. aOccurrence ≥3 months before randomization of eGFR <60 mL/min/1.73 m2, UACR ≥30 mg/g and/or ≥1 other marker(s) of kidney damage. bPatients unable to tolerate the dosage may be down-titrated only by reversing the assigned steps within the treatment group.